No Data
No Data
Lanwei Medical (301060.SZ): Has repurchased 0.41% of the shares in total.
On August 2, Gelunhui reported that Lanwei Medical (301060.SZ) has bought back a total of 1,640,200 shares of the company through the Shenzhen Stock Exchange stock trading system by centralized bidding trading method as of July 31, 2024, accounting for 0.41% of the company's current total share capital. The highest fill price was 14.23 yuan/share, the lowest fill price was 8.12 yuan/share, and the total trading amount was RMB 19,399,466.00 (excluding transaction fees). The implementation of the above-mentioned share repurchase plan by the company is in compliance.
Lanwei Medicine (301060.SZ): Cumulative expenditure of 19.3995 million yuan to repurchase 1.6402 million shares.
Lanwei Medical (301060.SZ) announced that as of June 30, 2024, the company has repurchased a total of 1,640,200 shares of the company through the Shenzhen Stock Exchange stock trading system using centralized bidding trading, accounting for 0.41% of the company's current total share capital. The highest fill price was 14.23 yuan/share, the lowest fill price was 8.12 yuan/share, and the total trading amount was RMB 19.3995 million (excluding transaction fees).
Labway Clinical Laboratory Names Chief Financial Officer
Lan Wei Medical (301060.SZ): Financial director changed to Wang Haiyang
Gelonghui, May 29丨Lan Wei Medical (301060.SZ) announced that the company recently received a written resignation report from Mr. Wang Xigu, the company's financial director. Mr. Wang Xigu applied to resign as financial director due to personal reasons. The original term of office expires on December 16, 2024. After resigning from the above position, Mr. Wang Xigu no longer held any position in the company. After review by the nomination committee of the board of directors of the company and the audit committee of the board of directors, the board of directors agreed to appoint Ms. Wang Haiyang as the company's financial director. The term of office will begin on the date of review and approval by the board of directors and end on the date the third board of directors expires.
Lanwei Medical (301060.SZ): The testing programs provided include eugenics and childbearing tests, prenatal screening, etc.
Gelonghui, May 10 | Lanwei Medical (301060.SZ) said on the investor interactive platform that the testing services provided by the company cover molecular tests, biochemical tests, immunological tests, basic clinical tests (clinical body fluids and blood tests), and physico-chemical tests. The service customers include medical institutions such as maternal and child health hospitals, and the testing items provided include eugenics and prenatal screening.
Shanghai Labway Clinical Laboratory (SZSE:301060) Has Debt But No Earnings; Should You Worry?
No Data